A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Abstract

Drug-resistant variants of herpes simplex viruses (HSV) have been reported that are not effectively treated with first-line antiviral agents. The objective of this study was to evaluate available literature on the possible efficacy of second-line treatments in HSV and the use of second-line treatments in HSV strains that are resistant to first-line treatments. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a final search was conducted in six databases on November 5, 2021 for all relevant literature using terms related to antiviral resistance, herpes, and HSV. Eligible manuscripts were required to report the presence of an existing or proposed second-line treatment for HSV-1, HSV-2, or varicella zoster virus (VZV); have full-text English-language access; and potentially reduce the rate of antiviral resistance. Following screening, 137 articles were included in qualitative synthesis. Of the included studies, articles that examined the relationship between viral resistance to first-line treatments and potential second-line treatments in HSV were included. The Cochrane risk-of-bias tool for randomized trials was used to assess risk of bias. Due to the heterogeneity of study designs, a meta-analysis of the studies was not performed. The dates in which accepted studies were published spanned from 2015-2021. In terms of sample characteristics, the majority (72.26%) of studies used Vero cells. When looking at the viruses on which the interventions were tested, the majority (84.67%) used HSV-1, with (34.31%) of these studies reporting testing on resistant HSV strains. Regarding the effectiveness of the proposed interventions, 91.97% were effective as potential managements for resistant strains of HSV. Of the papers reviewed, nectin in 2.19% of the reviews had efficacy as a second-line treatments in HSV, amenamevir in 2.19%, methanol extract in 2.19%, monoclonal antibodies in 1.46%, arbidol in 1.46%, siRNA swarms in 1.46%, Cucumis melo sulfated pectin in 1.46%, and components from Olea europeae in 1.46%. In addition to this griffithsin in 1.46% was effective, Morus alba L. in 1.46%, using nucleosides in 1.46%, botryosphaeran in 1.46%, monoterpenes in 1.46%, almond skin extracts in 1.46%, bortezomib in 1.46%, flavonoid compounds in 1.46%, andessential oils were effective in 1.46%, but not effective in 0.73%. The available literature reviewed consistently supports the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. Immunocompromised patients have been noted to be the population most often affected by drug-resistant variants of HSV. Subsequently, we found that HSV infections in this patient population are challenging to manage clinically effectively. The goal of this systematic review is to provide additional information to patients on the potentiality of second-line treatment in HSV strains resistant to first-line treatments, especially those who are immunocompromised. All patients,...

Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy

“…The herpes virus (HSV), comprising two serotypes (HSV-1 and HSV-2), is an enveloped virus with a nucleocapsid that protects a double-stranded DNA [4][5][6]. The advantages of the HSV as an oncolytic virus are as follows [7][8][9][10][11][12][13]: (i) a large genome and complex structure that enables the insertion of large fragments and multiple transgenes without limiting the viral efficiency; (ii) an ability to infect most types of malignant cells; (iii) flexibility in inserting multiple transgenes; (iv) despite the high frequency of anti-virus antibodies in a large proportion of the population, they do not prevent virus replication.…”

Bridging Flocculation of a Sterically Stabilized Cationic Latex as a Biosensor for the Detection of Microbial DNA after Amplification via PCR

“…One particular gene associated with this is the mecA gene . In addition, there are drug-resistant viral strains such as acyclovir-resistant HSV-2 . Currently, detection of antibiotic resistance in bacteria relies on the use of phenotypical testing, including disk diffusion tests, which rely on the exposure of a bacterial isolate to the antibiotics, and observing the inhibition of growth visually .…”

“… 21 In addition, there are drug-resistant viral strains such as acyclovir-resistant HSV-2. 22 Currently, detection of antibiotic resistance in bacteria relies on the use of phenotypical testing, including disk diffusion tests, which rely on the exposure of a bacterial isolate to the antibiotics, and observing the inhibition of growth visually. 23 Multiplex PCR can also be used to accurately identify AMR profiles of both bacteria and viruses, where there are numerous clinically relevant antimicrobial resistance genes.…”